The headline reads as positive (95% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › SUPN
Supernus Pharmaceuticals, Inc. (SUPN) stock analysis
WEAK BUY 27% confidence · analysed Oct 30, 2026
On Oct 30, 2026, our model rated Supernus Pharmaceuticals, Inc. (SUPN) WEAK BUY with 27% confidence at a price of $41.84. That means the signals lean positive, but they are mixed, so conviction is low.
Analysed price$41.84
Technical picture
The 14-day RSI is 46, close to the neutral 50 line, so momentum is balanced.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is 1.8x its 20-day average, so the latest move has real participation behind it.
Trend structure and money flow
Market structure shows a bearish break of structure (BOS): price broke a recent swing low in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $52.50 and the swing low is $42.45; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The company reports a profit margin of -13.2% and revenue growth of +32.4%.
In its latest quarter it earned $0.53 per share, which beat the $0.51 analysts expected, with revenue +32.4% year over year.
Wall Street's average rating is 1.5 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $60.50.
Trade plan from the model
The model's long / bullish plan uses an entry near $41.84, a target of $45.84 (+9.6%) and a stop-loss at $37.96 (-9.3%).
That is a reward-to-risk ratio of about 1.0 to 1: the potential gain is not much bigger than the loss, so the setup is marginal.
The plan has a time limit: reassess by Nov 9, 2026 whatever the price does.
Entry$41.84
Target$45.84
Stop-loss$37.96
Reassess byNov 9, 2026
Research notes
SUPN’s bull case is improving revenue momentum—Q3 2026 revenue rose about 18% year over year to $226.8 million—and potential long-term scale, cost synergies, and earnings leverage from its planned all-stock merger with Indivior. The bear case is weaker profitability and execution risk: reported Q3 EPS of $0.35 missed estimates, analyst earnings expectations have been reduced, and several firms rate the stock Sell or Reduce. The major recent catalyst is the Q3 earnings release and merger preparation, including termination of SUPN’s UBS credit line ahead of a planned replacement facility; despite the revenue beat, investor reaction was muted because profitability fell short.
The model's one-paragraph read
Leans BUY — composite score +0.27 (WEAK BUY). Technicals: RSI 46.49, MACD bullish, price below SMA50. Fundamentals: margin -13.2%, revenue growth 32.4%. Financial results: YoY revenue +32.4%, last EPS surprise +3.9%. Smart Money Concepts: BOS bearish (trend continuation), price retesting a bullish order block, price retesting a bearish order block. FinGPT news read: positive. Internet research: SUPN’s **bull case** is improving revenue momentum—Q3 2026 revenue rose about 18% year over year to $226.8 million—and potential long-term scale, cost synergies, and earnings leverage from its planned all-stock merger with Indivior. The **bear case** is weaker profitability and execution risk: reported Q3 EPS of $0.35 missed estimates, analyst earnings expectations have been reduced, and several firms rate the stock Sell or Reduce. The major recent catalyst is the Q3 earnings release and merger preparation, including termination of SUPN’s UBS credit line ahead of a planned replacement facility; despite the revenue beat, investor reaction was muted because profitability fell short. Suggested levels: entry $41.84, target $45.84, stop-loss $37.96, exit by 2026-11-09 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for SUPN
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 30, 2026 | WEAK BUY | 27% | $41.84 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on SUPN
Oct 30, 2026 · Supernus Pharmaceuticals, Inc. Reports Record Third Quarter 2026 Revenues of $226.8 million
- Oct 30, 2026: Supernus Pharmaceuticals, Inc. Reports Record Third Quarter 2026 Revenues of $226.8 million (Nasdaq)
- Oct 29, 2026: Supernus Ends Its Standalone Era With A Big Beat And Higher Guidance, But The Indivior Merger Now Drives The Story (Earnings Whispers)
- Oct 29, 2026: Supernus: Q3 Earnings Snapshot (Associated Press)
- Oct 29, 2026: Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600 (PR Newswire)
Frequently asked questions
Is SUPN a buy right now?
As of Oct 30, 2026, our automated model rates Supernus Pharmaceuticals, Inc. (SUPN) WEAK BUY with 27% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for SUPN?
The model's most recent plan targets $45.84 with a stop-loss at $37.96, from an entry near $41.84.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.